Fecal Transplant Therapy Market Report 2024

This Fecal Transplant Therapy market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The fecal transplant therapy market size has grown strongly in recent years. It will grow from $1.91 billion in 2023 to $2.02 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to rising awareness of fecal transplant procedures, increased demand for advanced treatments, heightened global consciousness, growing investments in research and development, and the rising prevalence of inflammatory bowel disease.

The fecal transplant therapy market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. Growth during the forecast period can be attributed to the increased adoption of biologics for treatment, a rising prevalence of chronic illnesses, growing use of biopesticides, an increase in prescriptions for novel drugs, and a higher number of patients with target medical conditions. Key trends in the forecast period include a greater focus on microbiome research, the development of synthetic alternatives, an increase in clinical trials, advancements in delivery methods, and enhanced donor screening processes.

The rising prevalence of inflammatory bowel disease (IBD) is expected to drive growth in the fecal transplant therapy market. IBD refers to chronic inflammation of the gastrointestinal tract, including conditions such as Crohn's disease and ulcerative colitis. The increasing number of IBD cases is attributed to factors such as the consumption of highly processed foods, inappropriate or frequent use of antibiotics, improved hygiene, and reduced exposure to infectious agents during childhood. Fecal transplant therapy aims to restore healthy gut microbiota, thereby reducing inflammation and alleviating symptoms in patients with IBD, potentially impacting disease management and progression. For example, in June 2023, Crohn's and Colitis Canada, a Canada-based non-profit organization, reported that the number of IBD patients in Canada is projected to reach 470,000 by 2035, up from an estimated 322,600 in 2023. Therefore, the increasing prevalence of IBD is fueling the growth of the fecal transplant therapy market.

Key companies in the fecal transplant therapy market are focusing on developing innovative treatments, such as pill-based fecal microbiota transplantation (FMT) therapy, to improve patient compliance and expand accessibility. Pill-based FMT therapy involves encapsulating live bacteria from donor feces into oral capsules, aiming to replenish healthy gut bacteria and enhance intestinal health. For instance, in April 2023, Seres Therapeutics Inc., a US-based biotechnology company, and Nestlé Health Science S.A., a Switzerland-based healthcare company, launched VOWST, an oral capsule treatment designed to prevent recurrent clostridioides difficile infection (rCDI) in adults following antibiotic treatment. Unlike traditional FMT, which involves transferring whole stool, VOWST utilizes live bacterial spores from healthy human donors, targeting the restoration of the gut microbiome.

In January 2022, OpenBiome, a US-based nonprofit organization, partnered with the University of Minnesota. This strategic collaboration allows OpenBiome to distribute FMT preparations developed by the University of Minnesota using good manufacturing practices, ensuring continued access to fecal microbiota transplantation for patients suffering from recurrent C. difficile infections. The University of Minnesota, a US-based public research institution, focuses on studying various diseases and treatments, including fecal transplant therapy.

Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children's Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women's Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California.

North America was the largest region in the fecal transplant therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal transplant therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fecal transplant therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fecal transplant therapy, or fecal microbiota transplantation (FMT), is a medical procedure that transfers stool from a healthy donor into a recipient's gastrointestinal (GI) tract. This treatment is primarily used to combat recurrent Clostridium difficile infections and other gut-related disorders by restoring the patient's gut flora with beneficial bacteria to enhance digestion and overall health.

The key methods of fecal transplant therapy include fecal enema, fecal bacteriotherapy, stool transplantation, human probiotic infusion, and fecal transfusion. Fecal enema involves introducing healthy donor stool into a patient's colon through an enema to rebalance gut bacteria. FMT is used to treat conditions such as Clostridium difficile infection, autism, obesity, Parkinson's disease (PD), diabetes mellitus, and others, and is administered in settings such as hospitals, specialty clinics, and other healthcare facilities.

The fecal transplant therapy market research report is one of a series of new reports that provides fecal transplant therapy market statistics, including fecal transplant therapy industry global market size, regional shares, competitors with a fecal transplant therapy market share, detailed fecal transplant therapy market segments, market trends and opportunities, and any further data you may need to thrive in the fecal transplant therapy industry. This fecal transplant therapy market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fecal transplant therapy market includes revenues earned by entities through donor screening and selection, stool processing and preparation, and post-procedure monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.